SCHEMBL3593367

SCHEMBL3593367

Cc1cccc(NC(=O)Nc2ccc(C)c(Nc3ccc4c(c3)NC(=O)C4=Cc3ccc[nH]3)c2)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 5/20 0.81
FLT3 P36888 11/20 0.72
FLT4 P35916 8/20 0.72
KIT P10721 7/20 0.72
KDR P35968 7/20 0.72
NTRK3 Q16288 4/20 0.71
PDGFRB P09619 2/20 0.71
CSF1R P07333 2/20 0.71
JAK2 O60674 1/20 0.71
ABL1 P00519 1/20 0.71
INSR P06213 1/20 0.71
LYN P07948 1/20 0.71
RET P07949 1/20 0.71
IGF1R P08069 1/20 0.71
MET P08581 1/20 0.71
ROS1 P08922 1/20 0.71
FGR P09769 1/20 0.71
SRC P12931 1/20 0.71
FLT1 P17948 1/20 0.71
FGFR4 P22455 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3593364 1.00 NTRK1 (0.81) NTRK1FLT3FLT4KITKDR
SCHEMBL3602811 0.94 NTRK1 (0.77) NTRK1FLT3FLT4KITKDR
SCHEMBL3602814 0.94 NTRK1 (0.77) NTRK1FLT3FLT4KITKDR
SCHEMBL3603764 0.93 FLT3 (0.80) NTRK1FLT3FLT4KITKDR
SCHEMBL3603766 0.93 FLT3 (0.80) NTRK1FLT3FLT4KITKDR
SCHEMBL3612105 0.92 NTRK3 (0.79) NTRK1FLT3FLT4KITKDR
SCHEMBL3612102 0.92 NTRK3 (0.79) NTRK1FLT3FLT4KITKDR
SCHEMBL3596155 0.92 NTRK1 (0.81) NTRK1FLT3FLT4KITKDR
SCHEMBL3596157 0.92 NTRK1 (0.81) NTRK1FLT3FLT4KITKDR
SCHEMBL3601218 0.92 NTRK1 (0.78) NTRK1FLT3FLT4KITKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US claimed
EP-2102190-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-09-23 EP claimed
WO-2008073480-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2008-06-19 WO claimed
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US disclosed
EP-2102190-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-09-23 EP disclosed
WO-2008073480-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NTRK2, PDGFRB, PDGFRA NTRK1 4/4885FLT3 127/4885FLT4 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.